検索対象:     
報告書番号:
※ 半角英数字
 年 ~ 
 年
検索結果: 3 件中 1件目~3件目を表示
  • 1

発表形式

Initialising ...

選択項目を絞り込む

掲載資料名

Initialising ...

発表会議名

Initialising ...

筆頭著者名

Initialising ...

キーワード

Initialising ...

使用言語

Initialising ...

発行年

Initialising ...

開催年

Initialising ...

選択した検索結果をダウンロード

口頭

PET imaging and biodistribution of $$^{64}$$Cu labeled monoclonal antibody

Paudyal, P.*; Paudyal, B.*; 飯田 靖彦*; 花岡 宏史*; 渡辺 智; 石岡 典子; 渡邉 茂樹; 高柳 恵美*; 吉岡 弘樹*; 織内 昇*; et al.

no journal, , 

Quantitative PET imaging using $$^{64}$$Cu labeled antibody was investigated by animal study. Anti CD20 antibody, NuB2 was conjugated with the chelator, DOTA and radiolabeled with $$^{64}$$Cu. For animal study, nude mice bearing lymphoma (Raji tumor) were injected with $$^{64}$$Cu-DOTA-NuB2. The PET imaging followed by the biodistribution studies were done at 10min, 24h and 48h post injection. PET imaging showed the significant $$^{64}$$Cu-DOTA-NuB2 accumulations in the tumor. Biodistribution studies also revealed the significant uptake in tumor than that in muscle region at any time point. This study demonstrated the utility of $$^{64}$$Cu labeled antibody as a diagnostic imaging agent for PET and the success can be translated into clinic for the quantitative targeted imaging with PET.

口頭

Production and utilization of new radioisotopes for theraputic and diagnostic applications in cancer

飯田 靖彦*; 花岡 宏史*; 吉岡 弘樹*; 高柳 恵美*; 渡邉 茂樹; 石岡 典子; 渡辺 智; 松橋 信平; Paudyal, P.*; 樋口 徹也*; et al.

no journal, , 

Some new radionuclides would be useful for cancer diagnosis and therapy. Our project is to prepare these radionuclides, to apply them to many radiopharmaceuticals and to investigate usefullness of those new radiopharmaceuticals. Radio immuno therapy (RIT) is one of the most promising treatments for cancer therapy. And assessment of radiation dose to both tumor and normal tissues is very important to RIT. PET can estimate radiation dose directly, but general positron emittors don't suit for labeling of antibody because of their short half-lives. $$^{64}$$Cu and $$^{76}$$Br have appropriate properties ($$^{64}$$Cu: T$$_{1/2}$$ = 12.7 hr, $$^{76}$$Br: T$$_{1/2}$$ = 16.1 hr) and they may have great potentials for immuno-PET. We have synthesized $$^{64}$$Cu or $$^{76}$$Br labeled monoclonal antibody and evaluated potentials for in vivo quantitative evaluation of RIT. And we synthesized $$^{76}$$Br labeled glucose ($$^{76}$$BrDG). We evaluated its utility for tumor diagnosis. These new radiopharmaceuticals are very useful for cancer diagnosis and therapy. We will develop various radiopharmaceuticals labeled with these new radionuclides and apply them to clinical medicine in future.

口頭

Imaging and localization of $$^{64}$$Cu labeled trastuzumab in Her2/neu overexpressing non-small cell lung cancer xenografts

Paudyal, P.*; Paudyal, B.*; 飯田 靖彦*; 花岡 宏史*; 渡辺 智; 石岡 典子; 渡邉 茂樹; 高柳 恵美*; 吉岡 弘樹*; 織内 昇*; et al.

no journal, , 

Non-small cell lung carcinoma (NSCLC) overexpress Her2/neu gene in approximately 20% of the cases. Trastuzumab a humanized monoclonal antibody targets Her2/neu and inhibits neoplastic cell proliferation and significantly increases survival of patients with advanced metastatic breast cancer. The present study aimed to determine the effect of trastuzumab in Her2/neu expressing NSCLC with $$^{64}$$Cu labeled trastuzumab using in vivo PET imaging. Imaging of Her2/neu expression was performed with $$^{64}$$Cu -DOTA- trastuzumab in H2170 tumor bearing mouse with PET. PET studies revealed relatively high accumulation of $$^{64}$$Cu -DOTA- trastuzumab in the Her2/neu overexpressing H2170 tumor at 48 h post injection. The success of $$^{64}$$Cu -DOTA- trastuzumab brought an insight to PET imaging of Her2/neu gene expression in NSCLC patients with $$^{64}$$Cu -DOTA- trastuzumab to define the patients who might be benefited with trastuzumab based therapy.

3 件中 1件目~3件目を表示
  • 1